tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Fredericks S et al. | Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. | 2006 | Transplantation | pmid:16969296 |
| Gralla J and Wiseman AC | Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. | 2009 | Transplantation | pmid:19502965 |
| Suzuki H et al. | Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. | 1997 | Transplantation | pmid:9293881 |
| Lee D et al. | Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. | 2017 | Transplantation | pmid:27779572 |
| Wozniak LJ et al. | Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. | 2015 | Transplantation | pmid:26038872 |
| Kuypers DR et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. | 2010 | Transplantation | pmid:20555228 |
| Sheikh AM et al. | Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. | 1999 | Transplantation | pmid:10440408 |
| Naesens M et al. | The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. | 2007 | Transplantation | pmid:17700162 |
| Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. | 1997 | Transplantation | pmid:9326428 |
| Kato T et al. | Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. | 2007 | Transplantation | pmid:17984834 |
| High KP | The antimicrobial activities of cyclosporine, FK506, and rapamycin. | 1994 | Transplantation | pmid:7517076 |
| Tze WJ et al. | In vitro effects of FK-506 on human and rat islets. | 1990 | Transplantation | pmid:1694319 |
| Tuteja S et al. | The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. | 2001 | Transplantation | pmid:11397967 |
| Reichenspurner H et al. | Optimization of the immunosuppressive protocol after lung transplantation. | 1999 | Transplantation | pmid:10428269 |
| Pilmore HL et al. | Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. | 2001 | Transplantation | pmid:11726837 |
| Ishizuka J et al. | Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. | 1993 | Transplantation | pmid:7506454 |
| Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
| Shapiro R et al. | Pediatric renal transplantation under tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10075598 |
| Kaplan B et al. | Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. | 1999 | Transplantation | pmid:10075604 |
| Mor E et al. | Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. | 1994 | Transplantation | pmid:7519800 |
| Erden E et al. | Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. | 1994 | Transplantation | pmid:7519801 |
| Morikawa K et al. | The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. | 1992 | Transplantation | pmid:1281561 |
| Jain A et al. | Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. | 2000 | Transplantation | pmid:10653398 |
| Textor SC et al. | Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. | 1993 | Transplantation | pmid:7685934 |
| Arzouk N et al. | Interaction between tacrolimus and fumagillin in two kidney transplant recipients. | 2006 | Transplantation | pmid:16421493 |
| Kandula P et al. | Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. | 2012 | Transplantation | pmid:23037007 |
| First MR et al. | New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. | 2013 | Transplantation | pmid:23619735 |
| Ninova D et al. | Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. | 2004 | Transplantation | pmid:15316360 |
| Ciancio G et al. | The use of Campath-1H as induction therapy in renal transplantation: preliminary results. | 2004 | Transplantation | pmid:15316372 |
| Berg UB et al. | Renal function before and long after liver transplantation in children. | 2001 | Transplantation | pmid:11544422 |
| Gruessner RW et al. | Mycophenolate mofetil in pancreas transplantation. | 1998 | Transplantation | pmid:9721799 |
| Emond JC et al. | Improved results of living-related liver transplantation with routine application in a pediatric program. | 1993 | Transplantation | pmid:7682738 |
| Dean PG et al. | Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. | 2008 | Transplantation | pmid:18431244 |
| Shoji T et al. | Operational tolerance to class I disparate lungs can be induced despite pretransplant immunization with class I allopeptides. | 2007 | Transplantation | pmid:18091523 |
| Kershner RP and Fitzsimmons WE | Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. | 1996 | Transplantation | pmid:8878385 |
| McLaren A | Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. | 2003 | Transplantation | pmid:14705621 |
| Devlin J et al. | Nitric oxide generation. A predictive parameter of acute allograft rejection. | 1994 | Transplantation | pmid:7522365 |
| Roberts CA et al. | Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. | 2002 | Transplantation | pmid:12364862 |
| Vincenti F et al. | A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. | 2002 | Transplantation | pmid:11907427 |
| Vafadari R et al. | Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. | 2012 | Transplantation | pmid:22960764 |
| McCarthy SA et al. | The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. | 1992 | Transplantation | pmid:1384186 |
| Dhar DK et al. | The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. | 1992 | Transplantation | pmid:1384188 |
| Bashuda H et al. | Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. | 1996 | Transplantation | pmid:8693525 |
| Nakajima K et al. | Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. | 1988 | Transplantation | pmid:2454521 |
| Hughes JR et al. | Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. | 1999 | Transplantation | pmid:10480422 |
| Cacciarelli TV et al. | Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1998 | Transplantation | pmid:9808490 |
| Wissing KM et al. | Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. | 2006 | Transplantation | pmid:17006324 |
| Gruessner RW et al. | Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. | 2008 | Transplantation | pmid:18192910 |
| Holman MJ et al. | FK506-associated thrombotic thrombocytopenic purpura. | 1993 | Transplantation | pmid:7678357 |
| Todo S et al. | Small intestinal transplantation in humans with or without the colon. | 1994 | Transplantation | pmid:7512291 |